Ruixin, an intelligent medical company in cardiovascular field, has completed a + round financing of RMB 50 million

category:Internet
 Ruixin, an intelligent medical company in cardiovascular field, has completed a + round financing of RMB 50 million


It is understood that this round of financing will be mainly used to accelerate the clinical application of core products, strengthen the research and development of other layout products within the platform, and the construction of the companys marketing and service system.

The ct-ffr developed by Ruixin does not need vasodilator, pressure guide wire and equipment, so it can be noninvasive, greatly reducing the risk of patients in the diagnosis process and effectively relieving patients tension. At present, it has passed the special approval procedure for innovative medical devices, and has reached clinical and scientific cooperation with top medical institutions in the field of cardiovascular and cerebrovascular diseases, such as Fuwai, anzhen, Fudan Zhongshan, etc. In terms of commercial operation, Ruixin ct-ffr products landed in 120 hospitals, realizing commercial landing.

The three founders of Ruixin, Zheng Lingxiao, LAN Hongzhi and Ma Jun, are all doctoral returnees from famous universities in the United States. Before returning home, they studied and worked in Johns Hopkins, Stanford, Dassault system, Da Vinci surgical robot and other institutions, and worked in the fields of medical imaging and fluid mechanics for many years. The core evidence of Ruixins approval comes from the completion of the first large-scale 330 prospective clinical trials in China. Nearly 100 more than the largest number of trials in the world. Ruixin developed and launched the worlds first fully automatic morphology + functionality coronary heart disease analysis algorithm. As long as doctors input images, in a short period of time, Ruixins platform can accurately analyze morphological information such as coronary artery stenosis and plaque, and calculate functional parameters such as ct-ffr, which are crucial to the diagnosis of coronary heart disease, so as to provide a one-stop total functional solution for radiologists and cardiologists. Source: Wang Fengzhi, editor in charge of Netease Technology Report_ NT2541

The three founders of Ruixin, Zheng Lingxiao, LAN Hongzhi and Ma Jun, are all doctoral returnees from famous universities in the United States. Before returning home, they studied and worked in Johns Hopkins, Stanford, Dassault system, Da Vinci surgical robot and other institutions, and worked in the fields of medical imaging and fluid mechanics for many years.

The core evidence of Ruixins approval comes from the completion of the first large-scale 330 prospective clinical trials in China. Nearly 100 more than the largest number of trials in the world. Ruixin developed and launched the worlds first fully automatic morphology + functionality coronary heart disease analysis algorithm. As long as doctors input images, in a short period of time, Ruixins platform can accurately analyze morphological information such as coronary artery stenosis and plaque, and calculate functional parameters such as ct-ffr, which are crucial to the diagnosis of coronary heart disease, so as to provide a one-stop total functional solution for radiologists and cardiologists.